Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database

H Nagasu, Y Yano, H Kanegae, HJL Heerspink… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Randomized controlled trials have shown kidney-protective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

HJL Heerspink, A Karasik, M Thuresson… - The lancet Diabetes & …, 2020 - thelancet.com
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease

MS Kelly, J Lewis, AM Huntsberry, L Dea… - Postgraduate …, 2019 - Taylor & Francis
Objective: To review glucose-lowering efficacy and changes in renal function associated
with sodium-glucose co-transporter 2 (SGLT2) inhibitors among patients with chronic kidney …

Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational …

AK Forbes, RJ Suckling, W Hinton… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To conduct a systematic review of observational studies to explore the real‐world
kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse …

SGLT2 inhibitors may offer benefit beyond diabetes

A Kang, MJ Jardine - Nature Reviews Nephrology, 2021 - nature.com
SGLT2 inhibitors may offer benefit beyond diabetes | Nature Reviews Nephrology Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis

S Seidu, SK Kunutsor, X Cos, S Gillani, K Khunti - Primary Care Diabetes, 2018 - Elsevier
Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors may have renal protective
effects in people with impaired kidney function. We assessed the use of SGLT2 inhibitors in …

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

AD Kaze, M Zhuo, SC Kim, E Patorno… - Cardiovascular diabetology, 2022 - Springer
Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …

T Toyama, BL Neuen, M Jun, T Ohkuma… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …

Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations

CM Khoo, C Deerochanawong… - Diabetes, Obesity …, 2021 - Wiley Online Library
Early onset of type 2 diabetes and a high prevalence of co‐morbidities predispose the Asian
population to a high risk for, and rapid progression of, diabetic kidney disease (DKD). Apart …

SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence

JA Davidson - Postgraduate medicine, 2019 - Taylor & Francis
Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes mellitus (T2DM)
and is associated with poor clinical outcomes, including an increased risk of all-cause and …